Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 888

Sort by

Sort Order Select

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Elena Vladimirovna Semenova, MD PhD, Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Tatiana A Bykova, MD PhD, Anna Osipova, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar Barhatov, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris V Afanasyev, MD PhD professor

Blood (2019) 134 (Supplement_1): 2050.

https://doi.org/10.1182/blood-2019-128163

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

Rémy Duléry, MD, Laure Lebras, MD, Sylvain Choquet, MD, Roberta Di Blasi, Ahmad Kanj AL Jijakli, Laurence Heuberger, Eolia Brissot, MD PhD, Giorgia Battipaglia, MD, Florent Malard, MD PhD, Clemence Mediavilla, MD, Anne Vekhoff, MD, Paul Coppo, MD PhD, Tounes Ledraa, MD, Zora Marjanovic, Elise Corre, MD, Simona Lapusan, MD, Malek Aoudjhane, MD, Ramdane Belhocine, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 786.

https://doi.org/10.1182/blood-2019-130651

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Lidiane Inês Da Rosa, MD, Wellington Fernandes da Silva, MD, Andre Abdo, MD, Eduardo M Rego, MD PhD, Vanderson Rocha, MD PhD, Juliana Pereira, MD PhD

Blood (2019) 134 (Supplement_1): 5284.

https://doi.org/10.1182/blood-2019-126307

Published: 2019

Journal Articles

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Ani Gvajaia, MD, Amelia Langston, MD, Natia Esiashvil, MD, Michael Graiser, PhD, Kelly Valla, PharmD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5657.

https://doi.org/10.1182/blood-2019-122467

Published: 2019

Journal Articles

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Joanne L C Tan, MBBS, Eric Wong, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Radha Ramanan, MBBS, Andrew B M Lim, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5662.

https://doi.org/10.1182/blood-2019-122363

Published: 2019

Journal Articles

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Brendan Rasor, PharmD, Tyler Dickerson, PharmD, Qiuhong Zhao, MS, Jonathan E Brammer, MD, Karilyn Larkin, MD, Samantha Jaglowski, MDMPH, Alice S. Mims, MD, Sam Penza, MD, Sumithira Vasu, MDMBBS, Sarah A Wall, MD, Basem M. William, MRCP,MD, Ayman Saad, MD, Julianna Roddy, PharmD, Hannah K. Choe, MD, Marcin Puto, PharmD

Blood (2019) 134 (Supplement_1): 5715.

https://doi.org/10.1182/blood-2019-123657

Published: 2019

Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 5654.

https://doi.org/10.1182/blood-2019-128248

Published: 2019

Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood (2019) 134 (Supplement_1): 1840.

https://doi.org/10.1182/blood-2019-125235

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Luke Mountjoy, DO, Daniel Almquist, MD, Henry Ofori, Pharm D, RPh, Marlene Girardo, MS, Margaret McCallen, Pharm D, RPh

Blood (2019) 134 (Supplement_1): 3262.

https://doi.org/10.1182/blood-2019-128644

Published: 2019

Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Blood (2019) 134 (Supplement_1): 3116.

https://doi.org/10.1182/blood-2019-123205

Published: 2019

Journal Articles

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roni Shouval, Adi Eshel, MSc, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, MD, Shalev Fried, Mika Geva, MD, Elizaveta Kouniavsky, Amir A Kuperman, MD MSc, Yoram Louzoun, PhD, Omry Koren, PhD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3265.

https://doi.org/10.1182/blood-2019-125433

Published: 2019

Journal Articles

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Alessandra Cupri, MD, Salvatore Leotta, MD, Uros Markovic, MD, Maria Grazia Camuglia, PhD, Giulio Antonio Milone, MD, Angelo Curto Pelle, MD, Valerio Leotta, MD, Mary Ann Di Giorgio, MD, Anna Bulla, MD, Di Marco Anna Lia, PhD, Gaetano Moschetti, MD, Giuseppe Milone, MD PhD

Blood (2019) 134 (Supplement_1): 3271.

https://doi.org/10.1182/blood-2019-127120

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity Conditioning Regimens in Children with Very High Risk Acute Lymphoblastic Leukemia (VHR ALL): A Single-Center Experience

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

TEAM Conditioning (Thiotepa, Etoposide, Cytarabine, Melphalan) Prior to Autologous Hematopoietic Stem Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Final Results from a Prospective Multicenter Study

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only